Protein kinase modulators and therapeutic uses thereof

Details Protein kinase modulators and therapeutic uses thereof Protein kinase modulators and therapeutic uses thereof

2007-12-04

2011-11-15

Chung, Susannah (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S646000, C564S336000, C568S047000, C568S336000

Reexamination Certificate

active

08058309

ABSTRACT:
The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

REFERENCES:
patent: 5217999 (1993-06-01), Levitzki
patent: 5773476 (1998-06-01), Chen et al.
patent: 2004/0127555 (2004-07-01), Snow et al.
patent: 95/24190 (1995-09-01), None
Levitzki, et al., “Tyrosine kinase inhibition: an approach to drug development”, Science, 267, 1782-88, Mar. 24, 1995.
Aaronson S. T., “Growth Factors and Cancer”, Science, 254:1146-1153 (1991).
Backstrom R. et al., “Synthesis of Some Novel Potent and Selective Catechol O-Methyltransferase Inhibitors”, J. Med. Chem., 32:841-846 (1989).
Berge S. M. et al., “Pharmaceutical Salts”, J. Pharm. Sci., 66(1):1-19 (1977).
Blum G. et al., “Substrate Competitive Inhibitors of IGF-1 Receptor Kinase”, Biochem., 39:15705-15712 (2000).
Gazit A. et al., “Tyrphostins I: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors”, J. Med. Chem., 32:2344-2352 (1989).
Goodson J. M., “Dental Applications”, Medical Applications of Controlled Release, 2:115-138 (1984).
Langer R., “New Methods of Drug Delivery”, Science, 249:1527-1533 (Sep. 28, 1990).
Levitzki A. et al., Tyrphostins—Potential Antiproliferative Agents and Novel Molecular Tools, Biochem. Pharm., 40(5):913-920 (1990).
Levitzki A., “Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction”, FASEB J., 6:3275-3282 (1992).
Levitzki A. et al., “Tyrosine Kinase Inhibition: An Approach to Drug Development”, Science, 267:1782-88 (Mar. 24, 1995).
Posner I. et al., “Kinetics of Inhibition by Tyrphostins of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor and Analysis by a New Computer Program”, Mol. Pharmacol., 45:673-683 (1994).
Saudek C. D. et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”, N. Engl. J. Med., 321:574-579 (Aug. 31, 1989).
Schlessinger J., “Signal transduction by allosteric receptor oligomerization”, TIBS, 13:443-447 (Nov. 1988).
Schlessinger J. et al., “Growth Factor Signaling by Receptor Tyrosine Kinases”, Neuron, 9(3): 383-391 (Sep. 1992).
Treat T. et al., “Liposome Encapsulated Doxorubicin Preliminary Results of Phase I and Phase II Trials”, Liposomes in the Therapy of Infectious Disease and Cancer, Lopez- Berestein and Fidler (eds.), Liss, NY, 353-365 (1989).
Ullrich A. et al., “Signal Transduction by Receptors with Tyrosine Kinase Activity”, Cell, 61:203-212 (1990).
Yaish P. et al., “Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors”, Science, 242:933-935 (Nov. 11, 1988).
Yoneda T. et al., “The Antiproliferative Effects of Tyrosine Kinase Inhibitors Tyrphostins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice”, Cancer Res., 51:4430-4435 (Aug. 15, 1991).

Affiliated with

Also associated with

Rating

Protein kinase modulators and therapeutic uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein kinase modulators and therapeutic uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein kinase modulators and therapeutic uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4256851